donislecel (Pending FDA Approval)

Brand and Other Names:Lantidra
  • Print

Dosing & Uses

Type 1 Diabetes Mellitus

Allogeneic pancreatic islet cellular therapy pending FDA approval for treatment of brittle type 1 diabetes mellitus (labile diabetes; brittle T1D) in adults whose symptoms are not well controlled despite intensive insulin therapy

Next:

Pharmacology

Mechanism of Action

Allogeneic pancreatic islet cellular therapy that provides transplanted islets from donated pancreata from deceased organ donors

Pancreatic islets regulate blood glucose levels through highly regulated, pulsatile secretion of multiple hormones in response to fluctuations in blood glucose; endocrine cells within pancreatic islets release insulin, glucagon, somatostatin, pancreatic peptide, and ghrelin

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.